Biotech entity
All 1 tracked stories fall under one category: pharma. Halozyme Therapeutics, Inc. is most often covered alongside Argenx, which appears in 1 of these 1 story. Source depth averages 3 original sources per story, versus 2.4 across the same-window beat baseline.
Last mentioned: Feb 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Halozyme Therapeutics, Inc. is most often covered alongside Argenx, which appears in 1 of these 1 story. Source depth averages 3 original sources per story, versus 2.4 across the same-window beat baseline. The average consequence score is 6, matching the 6 beat baseline for this window. Halozyme Therapeutics, Inc. appears in 1 tracked Biotech story from February 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Halozyme Therapeutics, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Halozyme Therapeutics reported robust Q4 2025 results, driven by record royalty revenue from its ENHANZE drug-delivery platform and key partnerships with Roche and Argenx. The company is positioning 2026 as a transformative year, centered on the high-stakes commercial launch of subcutaneous Opdivo in collaboration with Bristol Myers Squibb.
Source: fool.com · insidermonkey.com
Halozyme Therapeutics, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
